Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Beghetti, Maurice
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. [electronic resource] - European journal of heart failure 03 2019 - 352-359 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1879-0844
10.1002/ejhf.1375 doi
Acetamides--administration & dosage
Adult
Antihypertensive Agents--administration & dosage
Cardiac Surgical Procedures--adverse effects
Disease Progression
Double-Blind Method
Drug Monitoring--methods
Early Medical Intervention--methods
Female
Heart Defects, Congenital--complications
Humans
Hypertension, Pulmonary--diagnosis
Male
Middle Aged
Proportional Hazards Models
Pyrazines--administration & dosage
Treatment Outcome
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. [electronic resource] - European journal of heart failure 03 2019 - 352-359 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1879-0844
10.1002/ejhf.1375 doi
Acetamides--administration & dosage
Adult
Antihypertensive Agents--administration & dosage
Cardiac Surgical Procedures--adverse effects
Disease Progression
Double-Blind Method
Drug Monitoring--methods
Early Medical Intervention--methods
Female
Heart Defects, Congenital--complications
Humans
Hypertension, Pulmonary--diagnosis
Male
Middle Aged
Proportional Hazards Models
Pyrazines--administration & dosage
Treatment Outcome